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ABSTRACT
Cyclooxygenase-2 (COX-2) plays an important role in lung cancer development 
and progression. Using streptavidin-agarose pulldown and proteomics assay, we 
identified and validated Ku80, a dimer of Ku participating in the repair of broken DNA 
double strands, as a new binding protein of the COX-2 gene promoter. Overexpression 
of Ku80 up-regulated COX-2 promoter activation and COX-2 expression in lung cancer 
cells. Silencing of Ku80 by siRNA down-regulated COX-2 expression and inhibited tumor 
cell growth in vitro and in a xenograft mouse model. Ku80 knockdown suppressed 
phosphorylation of ERK, resulting in an inactivation of the MAPK pathway. Moreover, 
CBP, a transcription co-activator, interacted with and acetylated Ku80 to co-regulate 
the activation of COX-2 promoter. Overexpression of CBP increased Ku80 acetylation, 
thereby promoting COX-2 expression and cell growth. Suppression of CBP by a CBP-
specific inhibitor or siRNA inhibited COX-2 expression as well as tumor cell growth. 
Tissue microarray immunohistochemical analysis of lung adenocarcinomas revealed 
a strong positive correlation between levels of Ku80 and COX-2 and clinicopathologic 
variables. Overexpression of Ku80 was associated with poor prognosis in patients with 
lung cancers. We conclude that Ku80 promotes COX-2 expression and tumor growth 
and is a potential therapeutic target in lung cancer.
INTRODUCTION
Lung cancer is the leading cause of cancer-related 
death in the world [1]. Although the advances in diagnosis 
and treatment have been achieved, the five-year survival 
rate of lung cancer remains very low. Cancer metastases 
during lung carcinoma development is the major cause of 
high mortality and low survival rate [2]. Furthermore, the 
complexity and the real-time change of the key biomarkers 
during the process of lung carcinogenesis also caused 
its therapeutic difficulties [3-6].Therefore, discovering 
and understanding the regulatory mechanisms of lung 
carcinogenesis has become increasingly important to 
provide potentially effective therapeutic targets. 
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Cyclooxygenase-2 (COX-2), an important 
inflammation factor in cancer development and 
progression, has been extensively studied [7, 8]. As an 
inducible isoform of COX, COX-2 can convert archidonic 
acid into prostaglandin H2. It is inducible in response 
to certain stimuli such as growth factors and cytokines 
and is involved in many pathological processes such as 
inflammation and carcinogenesis [9, 10]. It was reported 
that more than 15% of malignant tumors were correlated 
with infection [11]. It has been well established that COX-
2 is up-regulated in a variety of cancers and promotes 
tumor growth [12, 13]. Overexpression of COX-2 and its 
metabolite prostaglandin E2 (PGE2) have been reported 
to contribute to increased angiogenesis [14, 15], apoptosis 
resistance [16-18], decreased host immunity [19, 20], and 
enhanced invasion and metastasis [21, 22]. 
The COX-2 gene, located at chromosome 1q25.2-25.3, 
is composed of 10 exons and 9 introns with approximately 
8.3 kb in size [23]. There are CAAT/enhancer binding 
protein (C/EBP) and cAMP response elements in the 
5’-terminal nucleotide sequence. There are also some 
other protein binding sites in these gene sequences, such 
as the activator protein-2 (AP-2), the nuclear factor-
kappa B (NF-κB) [24, 25] and some transcriptional co-
activators such as p300/CBP [26,27]. The expression 
of COX-2 is strictly and specifically regulated by these 
proteins. However, it remains unclear about how COX-
2 is over-activated during carcinogenesis. We postulated 
that there were some unknown tumor-specific COX-2 
promoter-binding proteins to regulate COX-2 expression 
in human cancers. In this study, we use streptavidin-
agarose pulldown assay and proteomics [28] techniques 
to discover and identify these potentially critical unknown 
regulatory factors of COX-2 in human lung cancer cells. 
One of the proteins was identified as Ku80, a DNA repair 
protein. It was detected in the COX-2 promoter DNA-
protein complexes eluted from nuclear extracts prepared 
only from lung cancer cells. 
Ku80 is a dimer of Ku, which is the regulatory 
DNA-binding region of the DNA-dependent protein 
kinase (DNA-PK). Ku80 has been implicated in several 
nuclear processes, including the repair of broken DNA 
double strands and V(D)J recombination [29], telomere 
maintenance, antigen receptor gene arrangements, 
regulation of specific gene transcription, apoptosis, 
regulation of heat shock-induced responses, as well as a 
newly identified role in regulation of the G2 and M phases 
of the cell cycle [30, 31]. Ku protein itself has also been 
reported to be able to function as transcription factors and 
bind in a sequence-specific manner to promoter elements 
[32]. For example, Ku86 binds to the promoter of the heat 
shock proteins, glucose-regulated peptide78, grp94 [33] 
and S100A9 and regulates their gene expression [34]. 
Interestingly, Ku70/80 also mediates adhesion of cells 
to fibronectin, which indicates its role as an adhesion 
receptor. Ku80 also appears to be coupled with signal 
transduction [35]. Recent reports suggest that there is a 
positive relationship between Ku and the development 
of cancer, making Ku an important candidate target 
for anticancer drug development [36,37]. Specifically, 
prior studies suggest that a delicate balance exists in Ku 
expression, as overexpression of Ku proteins promotes 
oncogenic phenotypes, including hyper-proliferation 
and resistance to apoptosis; whereas deficient or low 
expression of Ku leads to genomic instability and 
tumorigenesis [38, 39]. Inhibition of the expression 
of either Ku70 or Ku80 results in the inhibition of cell 
growth, the induction of apoptosis [40, 41] and attenuation 
of nuclear NF-κB p50 activity [42]. On the contrary, 
overexpression of Ku protein increases nuclear NF-κB 
activity in Rat fibroblast [43]. However, the role of Ku80 
or Ku70 in regulating cancer-related gene expression 
remains unclear enough, especially whether Ku80 or 
Ku70 controls COX-2 expression and activity directly or 
indirectly in lung carcinoma cells is largely unknown.
In this study, we used biotin-streptavidin pulldown 
assay to look for and identify the unknown and essential 
transcriptional regulators for COX-2 and found that 
Ku80 specifically bound to the COX-2 promoter and 
activated COX-2 transcription, and then increased COX-
2 expression and the production of its downstream 
molecule PGE
2.
 We also studied the clinical association 
between Ku80 and COX-2 in lung cancer tissue samples. 
In addition, we also investigated the possible association 
between CBP and Ku80 in mediating COX-2 transcription. 
All the results support our initial discovery that Ku80 
may act as an important regulator of COX-2 expression 
to participate in the development of lung cancer. Based 
on the important role of COX-2 in inflammation and 
infection-associated tumorigenesis, our findings, to some 
extent, suggests that Ku80 may serve as a potential novel 
therapeutic target for human lung cancer.
RESULTS
Discovery of COX-2 promoter-binding proteins in 
lung cancer cells
According to our previous study [44], we designed 
and synthesized a 479-bp biotin-labeled double-stranded 
oligonucleotide probe corresponding to the 5’-flanking 
sequence of the COX-2 gene from -30 to -508 as a DNA 
probe to pull down the transcriptional factors of COX-
2 gene and to assess their binding on COX-2 promoter 
region. Nuclear extracts prepared from human lung 
cancer cell lines (H1299 and A549), immortalized lung 
cell line (HBE) and normal lung cell lines (HLF) were 
incubated with biotin-labeled COX-2 promoter probe and 
streptavidin-agarose beads. After washing and elution, the 
COX-2 promoter-binding proteins were separated by SDS-
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PAGE and visualized through silver staining. As shown 
in Figure 1A, one of the protein bands (at about 90-100 
kDa) significantly appeared in the lung cancer cells and 
immortalized cells with high COX-2 expression but not in 
HLF cells. Next, we used proteomics approach to identify 
this specific COX-2 promoter-binding protein. The 
protein band was dissected from the gel and digested with 
trypsin. The peptide digests were further analyzed by mass 
spectrum and identified by searching an internationally 
recognized proteomics data library. The protein band 
was predicted to be Ku80, also called as X-ray repair 
complementing defective repair in Chinese hamster cells 
5 (XRCC5).
Validation of Ku80 as a COX-2 promoter-binding 
protein
To verify the binding of Ku80 at COX-2 promoter 
region in lung cancer cells, we performed immunoblot 
analyses for the proteins eluted from the biotin-
streptavidin pulldown complexes using anti-Ku80 
antibody. As shown in Figure 1B, the Ku80 was clearly 
detected in the complex prepared from the human lung 
cancer cell lines H1299, A549 and immortal cell line HBE 
but not from the normal lung cell line HLF, demonstrating 
the tumor cell-selective binding of Ku80 to the COX-2 
promoter. To further confirm that Ku80 functions as a 
special COX-2 promoter-binding protein in vivo, we 
analyzed the binding of Ku80 to the chromatin COX-2 
promoter in living cells by ChIP assay using a specific 
antibody against Ku80. Normal IgG was used as negative 
control. As shown in Figure 1C, COX-2 promoter was 
amplified in lung cancer and immortalized cells but not in 
normal lung cells, indicating the binding of Ku80 protein 
at the endogenous COX-2 promoter again. Compared to 
the three lung cancer cell lines A549, H460 and H322 and 
immortalized cell HBE with high expression of COX-2, 
a relatively weak Ku80 binding on COX-2 promoter was 
detected in normal lung cell line HLF and lung cancer cell 
H1299 with low expression of COX-2. The DNA binding 
was undetectable when using a normal IgG control in the 
ChIP assay. These results confirmed that Ku80 specifically 
bound to the COX-2 promoter in human lung cancer cells.
Regulation of Ku80 on COX-2 transcription 
activity and expression
Based on the results described above, we 
hypothesized that Ku80 might drive the transcription of 
COX-2 as a transcription regulator in lung cancer cells. 
To verify this, we constructed luciferase-reporter vector 
driven by COX-2 promoter with six different lengths 
(shown in Figure 2A). We co-transfected H1299 cells, 
which had low Ku80 expression, with the plasmids 
expressing Ku80 and a luciferase reporter driven by 
COX-2 promoter. As shown in Figure 2B, the luciferase 
expression was higher in cells co-transfected with Ku80 
and COX-2 (-459/+9 and -891/+9)-luciferase plasmids 
compared with those in cells co-transfected with Ku80 
and COX-2-luciferase plasmids with other lengths of 
COX-2 promoter regions, or cells co-transfected with 
LacZ and COX-2-luciferase plasmids. This result not only 
demonstrated that Ku80 drove the transcription of COX-2, 
but also indicated that Ku80 bound to the region of COX-2 
Figure 1: Ku80 was identified and validated as specific binding protein of COX-2 promoter in lung cancer cells. (A). 
The streptavidin-biotin pulldown assay was performed to find out the specific proteins which bind to COX-2 promoter. Nuclear extracts 
prepared from human lung cancer cell lines (H1299 and A549), immortalized lung cell line (HBE) and normal lung cell lines (HLF) were 
incubated with biotin-labeled COX-2 promoter probe (-508 to +30) and streptavidin-agarose beads. The DNA-protein complexes were 
separated by SDS-PAGE, and protein bands were visualized by silver staining. The arrow indicates the candidate COX-2 promoter-binding 
protein. (B). Immunoblot assay for detection of Ku80 binding to COX-2 promoter probe (-508 to +30). Ku80 protein in the DNA-protein 
complexes was detected by Western blot assay using anti-Ku80 antibody. (C). Chromatin immunoprecipitation assays were carried out 
using the COX-2 promoter from normal lung cell, immortal lung cell and various lung adenocarcinoma cells. PCR products were separated 
on 2% agarose gels. Normal IgG was negative control of Ku80 antibody.
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promoter at -363 to -459. 
To further verify the role of Ku80 in regulating 
COX-2 transcription, we blocked the expression of 
endogenous Ku80 using its specific siRNA in human 
lung cancer cells H460. We co-transfected H460, which 
had high expression of Ku80, with a Ku80-specific 
siRNA and a COX-2 (-459/+9)-luciferase plasmid. At 48 
hours after treatment, inhibition of Ku80 expression by 
siKu80-1, siKu80-2 or siKu80-3 attenuated the activity 
of COX-2 promoter (-459/+9) compared with negative 
control group (Figure 2C). The results indicated again 
the role of Ku80 as a transcriptional factor to drive the 
transcription of COX-2 in human lung cancer cells. 
Next, we further evaluated the effect of Ku80 on COX-2 
expression at protein and mRNA levels. We found that the 
ectopic expression of Ku80 significantly increased COX-
2 expression at the levels of protein and mRNA in H1299 
cells (Figure 2D). By contrast, the knockdown of Ku80 by 
Ku80 siRNA significantly decreased COX-2 expression in 
H460 cells (Figure 2E). 
Regulation of Ku80 on lung cancer cell 
proliferation and migration
Considering that the role of COX-2 in promoting 
cancer cell growth has been well established [9] and 
the results above indicated its regulation by Ku80, we 
speculate Ku80 could also accelerate lung cancer cell 
proliferation and migration. As shown in Figure 3A 
and 3C, inhibition of Ku80 expression with siKu80 
dramatically suppressed cell proliferation in lung cancer 
cell lines H1299 and H460. Similarly, H460 cells 
transfected with siKu80 showed lower activity of colony 
formation (Figure 3B). In addition, Ku80 knockdown also 
significantly inhibited cell migration (Figure 3E).
It is well known that MAPK is the downstream of 
COX-2. The activation of extracellular signal-regulated 
protein kinases (ERK1/2) is mainly associated with cell 
Figure 2: Ku80 bound to the COX-2 promoter region and regulated its transcriptional activation in lung cancer cells.
(A). A 5’-flanking DNA fragment from position -891 to +9 (-891/+9, -459/+9, -363/+9, -193/+9, -96/+9, -53/+9) of human COX-2 gene 
was constructed into a promoter-driven luciferase expression vector, pGL3. (B). H1299 cells were cotransfected with Ku80 and different 
COX-2 promoter-driven luciferase plasmids for 48 hrs. The proteins were extracted, and luciferase activity was detected by luciferase 
reporter assay kit. FLAG-lacZ plasmids were negative control. (C). H460 cells were cotransfected with siKu80 and COX-2 promoter-
driven luciferase (-459/ +9) plasmids. Luciferase activity was detected as described before. (D). Up-regulation of COX-2 mRNA and 
protein expression by Ku80 overexpression. H1299 cells were transfected with 2 μg/ mL of Ku80 plasmid or negative control lacZ for 48 
h, and the expression of COX-2 mRNA and protein were analyzed by RT-RCR and Western blot. (E). Down-regulation of COX-2 mRNA 
and protein expression by Ku80 knockdown. H460 cells were transfected with 1 μg/ mL of Ku80siRNA or nonspecific control siRNA for 
48 h, and the expression of COX-2 mRNA and protein were analyzed by RT-PCR and Western blot
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survival, proliferation, migration and cell growth, while 
p38 MAPK cascades are associated with the promotion 
of inflammation and programmed cell death [45,46]. 
We detected the MAPK family protein expression, and 
verified the role of Ku80 in activating MAPK proteins. As 
is shown in Figure 3D, the phosphorylation of ERK and 
p38 was inhibited by Ku80 knockdown, but the total level 
was not changed. From the results above, we concluded 
that Ku80 is specifically expressed in lung cancer cells 
and correlated with cell growth and proliferation partially 
through regulating MAPK signaling pathway.
Overexpression of Ku80 and COX-2 in lung 
carcinoma cells and tissues and their association 
with patients’ survival 
To confirm the correlation of Ku80 and COX-2 
and their biological and clinicopathologic significance in 
lung cancer patients, we first detected the expression of 
Ku80 and COX-2 in lung cancer cells and normal lung 
cells by Western blot. As shown in Figure 4A, Ku80 
was highly expressed in lung cancer cell line H322, 
A549, H460 and immortalized cell line HBE, whereas 
its expression was lower in lung cancer cell line H1299 
and normal lung cell HLF. While COX-2 nearly showed 
the same expression trend with Ku80 in these cell lines. 
Next, immunofluorescence analysis was used to further 
analyze the expression and sub-cellular localization of 
Ku80 in lung cancer cell. We found that Ku80 was highly 
expressed at nucleus in lung cancer H460 and A549 cells, 
but not in normal lung cell HLF (Figure 4B). We further 
detected Ku80 and COX-2 expression in lung cancer 
tissues and their corresponding adjacent non-cancer 
tissues by Western blot. Both Ku80 and COX-2 were 
highly expressed in lung cancer tissues compared with 
their adjacent non-cancer tissues (Figure 4C). Similarly, 
immunohistochemical staining showed that lung tumor 
tissues, but not their adjacent non-cancer tissues, had high 
expression of both Ku80 and COX-2 (Figure 4D). Three 
representative cases (Case 1, 2 and 3) were respectively 
from three different patients (Figure 4D). Among 72 
patients’ tumor tissue samples tested, about 43 (84.3%) 
patients showed high expression of both COX-2 and Ku80 
(Figure 4E). 
Additionally, the correlation of Ku80 and 
clinicopathologic variables and prognosis of 72 lung 
carcinoma patients were shown in Figure 5A and B. The 
overall survival analysis indicated patients with low COX-
2 and ku80 expression owned significantly higher survival 
Figure 3: Ku80 regulated the growth of lung cancer cells by inhibiting MAPK pathways. (A). Cell viability was analyzed 
by MTT in H1299 and H460 cells transfected with 1 μg/ mL siKu80 or nonspecific control siRNA for 48h were observed. (B). Colony 
formation assay of H460 cells transfected with 1 μg/ mL siKu80 or nonspecific control siRNA twice a week for two weeks was performed. 
The quantification of colonies was shown. (C). The morphology of H460 cells transfected with 1 μg/ mL siKu80 or nonspecific control 
siRNA for 48h were observed. The cell number was shown. (D). MAPK, p38 and their phosphorylation in H460 cell transfected with siKu80 
was respectively detected by Western blot assay using antibodies against p-ERK, ERK, p-p38, p38. And the quantitative measurement was 
shown below the Western blot. (E). Cell migration was analyzed by a wound-healing assay. H460 cells were seeded in 6-well plates and 
grown to full confluence. Cell migration was measured as described before, and the migration rate was calculated. The data are presented 
as the mean ± SD of three separate experiments. (*P<0.05, **P<0.01). 
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Figure 5: The clinical correlation analyses of Ku80 protein expression in 72 lung carcinoma patients. (A). Correlation 
analyses of Ku80 protein expression in relation to clinicopathologic variables of 72 lung carcinoma patients. (B). Cox-regression analyses 
for prognosis of 72 lung carcinoma patients. (C). Kaplan-Meier analysis of overall survival with high or low Ku80 expression ( P< 0.001, 
log-rank test). 
Figure 4: Ku80 and COX-2 were highly expressed in lung carcinoma cell and lung carcinoma tissues.(A). Ku80 and 
COX-2 expression in lung cancer cells, HLF and HBE cell lines were detected by Western blot using anti-Ku80 and COX-2 antibody. (B). 
The expression of Ku80 in lung cancer cells (H460 and A549) was detected by Immunofluorescence assay. The localization of Ku80 was 
shown. The red staining by secondary tetra methyl rhodamine isothiocyanate-conjugated antibodies was Ku80, and the blue staining by 
DAPI was nuclear. (C). The protein samples extracted from five couple of human lung carcinoma tissues and adjacent tissues were used to 
detected the expression of Ku80 and COX-2. (D) The immunostaining analysis of Ku80 and COX-2 protein expression from human lung 
adenocarcinoma tissue microarray. High expression of Ku80 and COX-2 were shown by being stained as brown, and low or no expression 
was shown in light. Case 1, Case 2 and Case 3 mean three representative cases respectively from three different patients. Tumor and 
adjacent tissues were from one patient for each case. (E). The correlation between the expression of Ku80 and COX-2 in lung carcinoma 
tissues from 72 patients was shown.
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rate compared to the patients with both high expression 
of these two proteins (P=0.01, Figure 5C). All the results 
demonstrated a potential correlation between Ku80 and 
COX-2 expression and their indication for the poor 
prognosis in lung cancer patients.
Inhibition of tumor growth by Ku80 knockdown 
through down-regulating COX-2 expression in 
mice
The effect of Ku80 on tumor growth was further 
examined in nude mice with human lung tumor 
xenografts. Human lung cancer cells H460 was injected 
subcutaneously into the armpit of nude mice. When the 
tumors were ~100 mm3 in size, the animals were treated 
with Ku80-specific siRNA and nonspecific control siRNA 
encapsulated by DC nanoparticles respectively. As shown 
in Figure 6A-C, the tumor volume and weight of mice 
treated with Ku80-specific siRNA was smaller and lighter 
compared with the group treated with non-specific RNA. 
To examine whether COX-2 expression is involved in 
Ku80-specific siRNA-mediated tumor growth suppression, 
we used LPS (lipopolysaccharides) to rescue COX-2 
expression in mice treated with Ku80-specific siRNA, 
and found that LPS partially rescued the tumor growth 
inhibition caused by Ku80 siRNA treatment (Figure 
6A-C). Furthermore, we examined the effect of Ku80 
knockdown on the expression of COX-2 at protein level 
in xenografts by Western blot and immunohistochemistry 
analysis. As shown in Figure 6D-E, Ku80-specific siRNA 
treatment attenuated COX-2 expression in xenografts. The 
results above demonstrated the important role of Ku80 
involved in lung tumor growth partially through regulating 
COX-2 expression.
Cooperation of Ku80 with CBP to co-regulate 
COX-2 expression 
As a transcription co-activator, CBP has been 
reported to participate in the transcription of COX-2 
through cooperating with NF-κB in many studies[26,27]. 
We therefore proposed that CBP might be involved 
in Ku80-mediated regulation of COX-2 expression 
similarly through synergy with Ku80 itself. To test this 
hypothesis, immunoprecipitation was performed. The 
nuclear extracts of lung cancer cells H1299, H460 and 
A549 were incubated with anti-Ku80 antibody, and then 
were immunoprecipitated with protein A/G-agarose 
beads. The complexes were then eluted and assayed by 
Western blot. As shown in Figure 7A, CBP protein was 
presented in the immune complexes precipitated by the 
antibodies against Ku80. Next, we further analyzed the 
co-localization of Ku80 with CBP in A549 and H460 cells 
by immunofluorescence analysis. As shown in Figure 7B, 
Figure 6: Ku80 knockdown inhibited tumor growth through down-regulating COX-2 expression in a mouse model. 
(A). A representative picture of nude mice comparing the sizes of tumor grafts 21 days after intratumoral injection of non-specific control 
siRNA (CON) or Ku80-specific siRNA. (B). The morphology of tumor xenografts of each nude mice after anatomy at 21 days of treatment. 
(C). Tumor volume of each group of nude mice was measured and calculated as V=(width2×length)/2. n=6; *, P<0.05. (D).The proteins 
were extracted from tumor xenografts. The Ku80 and COX-2 expression was detected by Western blot. (G) Immunohistochemistry assay 
of Ku80 and COX-2 expression from tumor xenografts in each group of nude mice.
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both Ku80 (red) and CBP (green) staining was detected 
in cell nucleus and had the same sub-cellular localization. 
These results indicated the existence of the interaction 
between Ku80 and CBP in lung cancer cells. 
CBP protein is thought to increase gene expression 
partially through its histone acetyltransferase (HAT) 
activity, which could acetylate histones and relax the 
chromatin structure at the gene promoter. Based on the 
cooperation between CBP and Ku80, we further detected 
the acetylation of Ku80 by CBP. Compared to the control 
group, CBP overexpression resulted in an increase in 
acetylated level of Ku80, and the treatment with C646, 
an inhibitor of CBP HAT activity, lowered the acetylated 
level of Ku80 (Figure 7C). While the expression of Ku80 
itself was not altered by CBP overexpression or activity 
inhibition by its inhibitor. These results demonstrated that 
CBP interacted with Ku80 and very possibly acetylated 
the latter to co-regulate gene expression in lung cancer 
cells. 
To verify the role of Ku80’s cooperation with 
CBP and the CBP-mediated acetylation of Ku80 in 
regulating COX-2 expression, we performed pulldown 
assay to analyze CBP’s effect on the binding of Ku80 at 
COX-2 promoter region. H1299 cells were respectively 
transfected with LacZ or CBP plasmid or treated with 
CBP inhibitor. As shown in Figure 7D, the binding activity 
of Ku80 on COX-2 promoter in the group treated with 
CBP inhibitor is significant lower compared with the 
control cells. Similarly, its binding activity in the group 
transfected with CBP plasmid was highly improved than 
the group treated with Lac Z plasmid. The results showed 
that the Ku80-mediated regulation of COX-2 expression 
might be realized under the help of CBP’s co-anchoring at 
COX-2 promoter region in lung cancer cells.  
To further confirm the effect of CBP on the up-
regulation of COX-2 expression mediated by Ku80, 
we detected the cell viability (Figure 7E) and COX-2 
expression (Figure 7F) in H1299 cells co-transfected with 
Ku80 plasmids and siCBP or CBP inhibitor C646 with 
Ku80 plasmids. Additionally, COX-2 promoter-driven 
luciferase activity was also tested in lung cancer cells 
cotransfected with COX-2 (-459/+9 promoter region)-
luciferase plasmids following the transfection with Ku80 
and siCBP or C646 treatment. As shown in Figure 7E-
F, cells transfected with Ku80 have higher cell viability 
and levels of COX-2 expression compared with cells 
transfected with the control plasmids. While the cells 
cotransfected with Ku80 and siCBP or C646 treatment 
Figure7: Ku80 interacted with CBP to co-regulate COX-2 expression in lung cancer cells. (A). The interaction of Ku80 and 
CBP was detected by IP assay using Ku80 antibody precipitated CBP from H1299, H460 and A549 cell nuclear extracts. The complex was 
detected by Western blot using anti-CBP antibody. IgG was used as negative control. (B). Co-localization of Ku80 and CBP in A549 and 
H460 cells by Immunofluorescence assay. The red staining by secondary tetra methyl rhodamine isothiocyanate was Ku80, and the green 
one by secondary fluorescein isothiocyanate -conjugated antibodies was CBP. (C). The nuclear extracted proteins from H460 cells treated 
with C464, and transfected with CBP plasmids were immunoprecipitated by anti-acetylation antibody. The complex was detected with anti-
Ku80 antibody. WCL represents the whole nuclear extracts. (D). The nuclear extracted proteins from H460 cells treated with C464, and 
transfected with CBP plasmids were incubated with COX-2 promoter probe (-459 to +9) and streptavidin-agarose beads. The complex was 
detected with anti-Ku80 antibody. (E). MTT was performed in H1299 cells transfected with Ku80, Ku80 and siCBP, or Ku80 and C464. (F). 
The COX-2 expression in H1299 cells transfected with Ku80, Ku80 and siCBP, or Ku80 and C464 treatment after stimulation with LPS. 
(G). The COX-2 promoter activity was detected in H1299 cells co-transfected with COX-2 promoter (-459/+9)-driven luciferase plasmids 
and Ku80 plasmids, or Ku80 and siCBP or Ku80 and C646. 
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showed lower cell viability and COX-2 expression 
level compared with the cells transfected with Ku80. 
Similarly, the treatment with siCBP or C646 after Ku80 
transfection significantly decreased COX-2 promoter 
activity compared with Ku80 plasmids treatment alone 
(Figure 7G). All the results suggested that Ku80 promoted 
up-regulation of COX-2 expression through cooperation 
with CBP and being acetylated by the latter.
DISCUSSION
In this study, we discovered and identified several 
potentially critical proteins which bound to COX-2 
promoter and activated its transcription in human lung 
cancers using streptavidin-agarose pulldown assay and 
high-throughput proteomics. Ku80 was chosen because of 
the same trend of Ku80 and COX-2 expression in different 
lung normal cells and cancer cells. The expression of 
Ku80 is higher in human lung adenocarcinomas than that 
in normal lung cells, so did the expression of COX-2. 
Ku80 can enhance the expression of the COX-2 promoter-
driven luciferase reporter gene and COX-2 protein itself, 
whereas the inhibition of Ku80 by its specific siRNA did 
the opposite. Knockdown of Ku80 also inhibited lung 
cancer cell growth by decreasing COX-2 expression in 
vitro and in vivo. Furthermore, the expression of Ku80 
was positively correlated with that of COX-2 through 
IHC assay in lung adenocarcinoma specimens. All the 
results uncovered the new role of Ku80 as a tumor-specific 
regulator of COX-2 in lung carcinoma, and also provided 
a new possibility to develop Ku80 as a potential anti-
cancer therapeutic target.
It is reported that the level of COX-2 expression is 
low in most normal tissues, while it is up-regulated in a 
variety of cancers and promotes their tumorigenesis and 
development [8, 9]. Genetic knock-out or pharmacological 
inhibition of COX-2 has been shown to protect against 
experimentally-induced carcinogenesis [47]. Furthermore, 
more and more studies focus on the announcement of new 
transcriptional regulators of COX-2 [24, 25]. Therefore, it 
is interesting and more significant to find out the unknown 
specific factors in regulating COX-2 expression in cancer 
cells and further explore how COX-2 is activated by these 
regulatory factors during tumorigenesis and development. 
In this study, we established the possibility of Ku80’s 
binding to COX-2 promoter and confirmed its regulation 
on COX-2 expression in lung adenocarcinomas though 
pulldown assay, ChIP, and other series of experiments. 
A completely new role of Ku80 as a transcriptional 
factor has been revealed in our study, not only that, such 
transcriptional regulatory role was found to be partially 
realized through controlling COX-2 expression. 
As a DNA repair protein, Ku80 is crucial in 
maintaining normal function and genetic stability 
of mammalian cells, acting as a tumor suppressor in 
carcinogenesis. However here Ku80 is reported as a tumor 
promoter. The contrary effects of Ku80 might be explained 
from two aspects. The first one is the complexity and 
real-time change of the cancer-related protein, just like 
p53, which has multiple functions in the development of 
cancer. At the initiation stage, Ku80 might act as a tumor 
suppressor in carcinogenesis and can repair the damaged 
DNA. With the development of tumor, the role of Ku80 
in DNA damage repair might be gradually weakened, and 
its role in regulating the expression of the cancer-related 
genes such as COX-2 might be improved. The second 
reason might be the diversity and complexity of COX-
2 transcription regulation. The expression of COX-2 is 
tightly controlled not only by the known protein factors 
such as AP-1, NF-kB, C/EBPβ and p300, but also by 
some unknown and new protein factors such as Ku80. 
These new protein factors maybe interact with the known 
protein factors directly or indirectly to up-regulate COX-2 
expression and promote tumor growth. Further studies are 
still needed to explore the exact molecular mechanisms of 
Ku80 in the regulation of COX-2 expression and tumor 
growth. 
CBP, a transcription co-activator, can bind to the 
NF-κB family proteins and co-regulate COX-2 expression. 
Also, it associates with SP-1 and AP-2 to co-regulate 
hTERT expression [26] in the previous reports. All the 
findings provided the possibility that CBP participated in 
the regulation of COX-2 through co-anchoring with Ku80 
at COX-2 promoter region. We verified this hypothesis by 
a serial experiments, including IP and IF assay, test of the 
acetylated level of Ku80, and the binding assay of Ku80 at 
COX-2 promoter region affected by CBP level. The results 
show that CBP did interact with Ku80 and acetylate it to 
co-regulate the transcriptional activity of COX-2 in lung 
cancer cells. 
COX-2 promoter activation and expression is 
regulated by multiply transcriptional factors such as AP-
1, C/EBPβ and NF-κB [47, 57]. Each pro-inflammatory 
mediator requires binding of a combination of different 
transactivators to their respective enhancer elements. 
Several reports have also shown that transcription co-
activator p300 is involved in the regulation of COX-2 
expression. P300 and CBP have a high degree of sequence 
homology. It is generally believed that they have similar 
functions and play redundant roles in gene expression. 
Considering the complexity of the transcription regulation 
of COX-2, besides CBP, there must be some other protein 
factors involved in the association with Ku80 directly or 
indirectly in co-mediating COX-2 expression. Further 
studies will be done in our future research to explore 
these underlying molecular mechanisms involved in the 
regulation of COX-2 expression.
Our study also provided the clinical evidence 
that the Ku80 regulated COX-2 expression. Both Ku80 
and COX-2 proteins were highly expressed in tumor 
tissues compared to adjacent non-malignant lung tissues. 
Moreover, the lung adenocarcinoma patients with high 
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Ku80 and COX-2 expression had a significantly shorter 
OS than those with low Ku80 and COX-2 expression. All 
the results suggested the significant correlation between 
COX-2 and Ku80 expression (P<0.001). However, Ku80 
expression shows no significant meanings to five-year 
survival (P>0.05) in the Cox-regression analyses for 
prognosis on multiple factors. It may be caused by the 
original function of Ku80. As one dimer of Ku, Ku80 
plays a very important role in DNA damage repair, which 
is a crucial process in maintaining normal function and 
genetic stability of mammalian cells [48, 49]. Once DNA 
damage repair was destroyed, apoptosis might be caused 
or even more seriously carcinogenesis arised [50, 51]. 
Therefore, the lower level of Ku80 might be one reason 
to cause cancer. On the contrary, a new report showed 
that lung tumors, compared with normal tissues, exhibited 
a significant overexpression of a wide number of DNA 
damage repair genes, mostly associated with DSBR, PRR, 
DNA replication, and telomere maintenance pathways 
[36, 37]. Therefore, the expression level of Ku80 in cells 
should be extraordinary significant for cells’ normal 
ability. Especially in carcinogenesis and development, 
it might play the role of a double-edged sword. The 
inconsistencies of expressions of COX-2 and Ku80 in 
12 tumor samples, which contained high levels of COX-
2 but low levels of Ku80, was also found in our study, 
suggesting that besides Ku80, there must be some other 
factors involved in the regulation of COX-2 expression 
in lung adenocarcinomas, such as NF-κB, AP-1/2,C/EBP 
and so on. The previous studies have revealed the diversity 
and complexity of COX-2 transcriptional regulation. Thus, 
our current study adds a new mechanism to the body of 
researches on the transcriptional regulation of COX-2, 
which is that COX-2 is a direct transcriptional target of 
Ku80 and its regulation is partially and might be critically 
controlled by Ku80 in lung adenocarcinoma cells.
In summary, our study verifies that Ku80 up-
regulates COX-2 promoter activity and further activates 
the expression of COX-2 in lung cancer cells. Such 
transcriptional activation ability of Ku80 in mediating 
COX-2 gene expression may be realized through co-
auchoring with CBP at COX-2 promoter elements 
and being acetylated by the latter. Ku80 knockdown 
inhibited lung tumor growth in vitro and in vivo. The lung 
adenocarcinoma patients with high expression levels of 
Ku80 and COX-2 protein had shorter survival periods. All 
the evidence provided the potential to develop Ku80 as a 
useful therapeutic target in some key stages of lung cancer 
progression.
MATERIALS AND METHODS
Cell lines and cell culture
Human lung cancer cell lines (H1299, A549, H322, 
H460) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA) and cultured in RPMI-
1640 medium (Gibco), supplemented with 10% fetal 
bovine serum. Normal human bronchial epithelial cell line 
(HBE) and human lung fibroblast cell (HLF) were also 
got from ATCC and maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine 
serum. All the cells were incubated at 37°C in a humidified 
atmosphere with 5% carbon dioxide 
Streptavidin-agarose pulldown assay
Streptavidin-agarose pulldown assays were done 
as described previously [47]. The biotin-labeled double-
stranded oligonucleotide probe, which corresponds 
to -30/-508 fragments of COX-2 promoter sequence 
were synthesized by TAKARA Company (sense, 
5’-ACGTGACTTCCTCGACCCTC-3’; antisense, 
5’-AAGACTGAAAACCAAGCCCA-3’). The assay 
was performed by mixing 400 μg nuclear proteins from 
different cell lines, 4 μg of the double-strand biotinylated 
probe and 50 μl of steptavidin-agarose beads solution 
(Sigma) and was incubated on a rotating wheel at room 
temperature for 2 hours. The beads were then pelleted by 
centrifugation at 600×g for 1 min and then washed 3 times 
with 200 μl PBSI each time. The collected beads were 
finally resuspended with 30 μl loading buffer and cooked 
at 100 °C for 5 min. The supernatant containing the bound 
proteins was separated by SDS-PAGE for further analysis.
Identification of COX-2 promoter-binding 
proteins
The COX-2 promoter-binding proteins were 
separated by 10% SDS-PAGE and visualized by silver 
staining according to the suggested protocol (Beyotime, 
China). The protein bands of interest in the gel were cut 
and digested with trypsin. The identification of digested 
samples was performed through mass spectrometry 
analysis. The proteins indicated by the bands of interest 
were further identified via searching the available 
proteomics databases.
Western blot analysis
Western blot analyses were performed according to 
the protocols for the routine with antibodies against Ku80, 
COX-2 (Abcam), CBP( CST, USA), β-actin and GAPDH 
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(Proteintech group, CA) respectively. 
Chromatin immunoprecipitation assay (ChIP)
The ChIP assay was performed as previously 
described [52]. Briefly, 1% formaldehyde was added 
to the culture medium of cells for 10mins, and 0.125M 
glycine was added to stop cross-linking. The cells were 
rinsed twice with ice-cold PBS, scraped, and collected by 
centrifugation. The cells were resuspended with 500 μl IP 
Buffer (100 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, 
pH 8.0, 0.02% NaN
3
, 10% SDS, 5.0% Triton X-100) for 
sonication for three times with 20s each, and the debris 
was removed by centrifugation. 50 μl lysate was used as 
the DNA input control and the remaining was incubated 
with anti-Ku80 antibody or non-immune rabbit IgG 
overnight at 4°C. Immunoprecipitated complexes were 
collected using protein A/G agarose beads and were 
extensively washed with Micelle Wash Buffer, Buffer 
500, LiCl/ detergent solution, TE Buffer, respectively. 
Then 1% SDS and 0.1 M NaHCO
3
 was added to the 
immunoprecipitates to be incubated at 65°C overnight, 
followed by treatment with 400 μg/ml proteinase K 
for 2 h at 37°C. The DNA was extracted with phenol/ 
chloroform and precipitated with ethanol. Final pellets 
were resuspended in 100 μl ddH
2
O and subjected to 
PCR amplification using specific COX-2 promoter 
primers (5’-primer, ACGTGACTTCCTCGACCCT C; 
and 3’-primer, CAGGCGCACAGGTTTCCGCC). The 
resulting product of 238 bp for the COX-2 promoter was 
separated by 1% agarose gel electrophoresis.
Plasmid vector
A 5’- flanking DNA fragment from position -891 to 
+9 (-891/+9, -459/+9, -363/+9, -193/+9, -96/+9, -53/+9) 
of human COX-2 gene was constructed into a promoter 
luciferase expression vector, pGL3 [44, 52]. The Ku80 
and CBP expression vectors pEGFP-C1-FLAG-Ku80 
and FLAG-CBP and the control vector FLAG-lacZ were 
designed and purchased from Addgene (US).
siRNA design and transfection 
The siRNAs targeting Ku80 (siRNA1: 
5’-GGCUCCAAUUUGUCUAUAATT- 3’; 
5’-UUAUAGACAAAUUGGAGCCTT-3’. siRNA2: 
5’-GGUGGCCAUAGUUCGAUAUTT-3’; 
5’-AUAUCGAACUAUGGCCACCTT-3’. siRNA3: 
5’ GAGCAGCGCUUUAACAACUTT-3’; 5’- 
AGUUGUUAAAGCGCUGCUCTT-3’.) ,siRNA 
targeting CBP (5’-GAGGUCGUUUACAUAAATT-3’; 
5’-UUUAUGUAAACGCGACCUCTT-3’) 
and negative control siRNA(5’-
UUCUCCGAACGUGUCACGUTT-3’;5’- 
ACGUGACACGUUCGGAGAATT-3’) were purchased 
from ShangHai GenePharma Co (Shanghai, China). Cells 
plated in 96-well plates (5,000 cells/well) or six-well 
plates (200,000 cells/well) were transfected with siRNA 
duplexes (1-2 μg) encapsulated by DC-nanoparticles. 
At 48 hours after treatment, protein expression and cell 
viability were tested by Western blot, RT-PCR and MTT 
analysis, respectively.
Nuclear extraction 
Nuclear extraction was performed as previously 
described [53]. Cells were lysed in 250 μl cytoplasm 
lysis buffer( 10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM 
MgCl
2
·6H
2
O, 0.5% NP-40, 300mM Sucrose) with multiple 
protease inhibitors(1 mM Na
3
VO4, 10 mM NaF, 2.5 mM 
β-glycerophosphate, 0.1 mM PMSF, 1 g/ml leupeptin, and 
0.5 mM dithiothreitol) on ice for 10 min. The mixture was 
vortexed briefly, and centrifuged at 2600×g for 1 min at 
4 °C. The supernatant was removed to a new tube, and 
stored at -80 °C. The pellet was resuspended with 70-
100 ul Nuclei lysis buffer (20 mM Hepes, pH 7.9, 420 
mM NaCl, 1.5 mM MgCl
2
·6H
2
O, 0.1 mM EDTA, 2.5% 
Glycerol) with multiple protease inhibitors and kept on ice 
for 30 mins. Nuclei proteins were extracted by centrifuge 
at 10400×g for 10 min at 4 °C. The supernatant was nuclei 
extracts. Protein concentration was determined by BCA 
assay.
Analysis of COX-2 promoter activity 
Cells (200,000 cells/ well) plated in six-well 
plates were transfected with the COX-2 promoter 
luciferase plasmids encapsulated with DC-nanoparticles. 
Meanwhile, cells were co-transfected with either Ku80 
overexpression vector (pEGFP-C1-FLAG-Ku80) or with 
lacZ overexpression vector used as control (FLAG-lacZ) 
or Ku80-specific siRNA or negative control siRNA used as 
control. 48 hours after treatment, the expressed luciferase 
activity was measured as described using a DUAL-
luciferase reporter assay kit[54] (BioVision, Inc.CA, 
USA). The ratio of firefly luciferase to Renilla luciferase 
activity (relative luciferase activity) was calculated to 
correct the variations in transfection efficiency. 
RT-PCR
Total RNA was prepared from cultured cell lines 
by using Trizol Reagent (TaKaRa Bio.) according to 
the manufacturer’s instructions. The PCR primers 
corresponding to COX-2, Ku80 and GAPDH functional 
gene sequences were synthesized by TaKaRa, and the 
sequences were as following: for COX-2 (sense:5’-
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TCACAGGCTTCCATTGACCAG-3’,antisense:5’-
CCGAGGCTTTTCTACCAGA-3’, for Ku80 
(sense:5’-TGACTTCCTGGATGCACTAATCGT-3’; 
5’-TTGGAGCCAATGGTCAGTCG-3’), for GAPDH 
(sense:5’–AATCCCATCACCATCTTCC-3’;antisense:5’-
CATCACGCCACAGTTTCC-3’). RT-PCR was carried 
out as described before [55]. The samples were first 
denatured at 98°Cfor 3 min, followed by 30 PCR cycles, 
each with temperature variations as follows: 98°C for 
10 s, 58°C or other annealing temperature for 30 s, and 
72°C for 30 s. The PCR products were visualized under 
ultraviolet light and the band density was measured 
through quantitative analysis.
Immunofluorescence and confocal microscopy
The Cells were seeded onto coverslips in a 6-well 
plate and fixed with 4% paraformaldehyde (w/v) for 30 
mins, and then were washed for 10 mins with PBS and 
permeabilized with 0.2% (w/v) Triton X-100 in PBS for 
5 mins. The blocking step was performed for 30 min in 
PBS containing 1% bovine serum albumin (BSA). Cells 
were then incubated overnight with the primary Ku80 
or CBP antibodies diluted in PBS containing 10% BSA. 
After being washed with PBS, cells were incubated for 1 h 
with secondary fluorescein isothiocyanate or tetra methyl 
rhodamine isothiocyanate -conjugated antibodies. After 
several additional washing steps, the cells were stained 
with DAPI (Beyotime, China). The localization of Ku80 
and CBP protein was assessed using a Leica DM 14000B 
confocal microscopy. 
MTT assay for cell proliferation
Cell viability was determined by the MTT assay 
(Roche Diagnosis, Indianapolis, IN). Briefly, the H1299 
and H460 cell lines seeded in 96-well plates (2,000 cells/ 
well) were treated with siRNA of Ku80 or negative control 
siRNA at the indicated doses. 48 hours after treatment, the 
cell viability was determined.
Clone formation assay
To analyze the effect of Ku80 on the clonogenicity 
of tumor cells in vitro, we transfected H460 cells (1,000 
cells/ well) seeded in six-well plates with siRNA of Ku80 
or control siRNA using DC nanoparticles. After 14 days, 
the cells were washed with PBS and fixed with fixation 
solution (methanol: glacial: acetic 1:1:8) for 10 min, and 
stained with 0.1% crustal violet for 30 mins. The clones 
with more than 50 cells were counted under an optical 
microscope.
In vitro migration assay
Scratch assay (wound healing assay) was performed 
to detect cell migration. The cells were grown to full 
confluence in six-well plates and wounded with a sterile 
100 μL pipette tip after 4 h of serum starvation and then 
transfected with 1 μg/ mL siKu80 for 8 h. Then refresh 
with full medium and keep in a CO
2
 incubator. After 48 
h, medium was replaced with phosphate buffered saline 
(PBS) buffer, the wound gap was observed, and cells were 
photographed using a Leica DM 14000B microscope fitted 
with digital camera.
Tissue microarray and immunohistochemistry 
analysis
The human lung adenocarcinoma tissue microarray 
used for immunostaining analysis of Ku80 and COX-
2 protein expression was purchased from Shanghai 
Outdo Biotech (Shanghai, China) and contains 72 lung 
adenocarcinomas and their corresponding adjacent non-
malignant lung tissues. The overall survival (OS) for 
the corresponding patients was calculated from the day 
of surgery to the day of death or to the last follow-up. 
The tissue microarray (TMA) slides were deparaffinized 
in xylene, rehydrated in graded alcohol, submerged 
into EDTA antigenic retrieval buffer and microwaved 
for antigenic retrieval, followed by treatment with 3% 
hydrogen peroxide in methanol to quench the endogenous 
peroxidase activity and incubation with 3% bovine 
serum albumin to block the nonspecific binding. Rabbit 
polyclonal anti-Ku80 (1:100; Santa Cruz) and COX-2 
(1:200; Abcam) antibody were incubated with the TMA 
overnight at 4 °C. For negative controls, the primary 
antibody was replaced by normal rabbit serum and then 
were treated with biotinylated anti-rabbit secondary 
antibody (protein tech, US), followed by incubation with 
streptavidin horseradish peroxidase complex (CST). The 
degrees of immunostaining were reviewed and scored by 
two independent observers. The proportion of the stained 
cells and the extent of the staining were used as criteria 
of evaluation. For each case, at least 1,000 tumor cells 
were analyzed and the percentage of the tumor cells 
with positively stained nuclear was recorded. For each 
sample, the proportion of Ku80 and COX-2-expressing 
cells varied from 0% to 100%, and the intensity of nuclear 
staining varied from weak to strong. One score was given 
according to the percentage of positive cells as:<5% of 
the cells:1 point; 6-35% of the cells:2 point; 36-70% of 
the cells:3 point; >70% of the cells: 4 point. Another 
score was given according to the intensity of staining as: 
negative staining: 1 point; weak staining (light yellow): 2 
point; moderate staining (yellowish brown): 3 point; and 
strong staining (brown): 4 point. A final score was then 
calculated by multiple the above two scores. If the final 
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score was equal or bigger than four, the protein expression 
in the tumor was considered high; otherwise, the protein 
expression in the tumor was considered low [56].
Acquisition of carcinoma tissue samples
Lung cancer samples and adjacent non-carcinoma 
tissues were collected at the first affiliated hospital of 
Dalian Medical University (Dalian, China) from patients 
of squamous cell carcinoma with different histological 
types (n=3). All the samples were stored at −80°C until 
western blot analysis. Informed consent was obtained 
from each patient and the whole study was approved by 
the Committees on Human Rights in Research at Dalian 
Medical University. 
Xenograft mouse model and tumor/tissue 
processing
Animal experiments were carried out in accordance 
with the National Institute of Health Guide for the Care and 
Use of Laboratory Animals under the approval of the SPF 
Laboratory Animal Center at Dalian Medical University 
[57]. H460 cells (5x106) were inoculated subcutaneously 
into the armpit of the nude mice. Once palpable tumors 
were observed, tumor volume measurements were taken 
every four days using calipers. Mice were randomly 
divided into 4 groups (5 mice per group) after the 
tumor volume reached 50 mm3,: (a) control siRNA; (b) 
Ku80 siRNA; (c) Ku80 siRNA+ LPS(10 μg / kg body 
weight[58]); (d) control siRNA + LPS. For delivery of 
DC nanoparticles-conjugated siRNA, 10 μg siRNA in 
0.1 ml saline buffer was injected intratumorally twice a 
week for 3 weeks [59]. The tumor volume was calculated 
as V= (width2×length)/2 using digital calipers. At last, the 
mice were sacrificed and the tumor size and weight was 
photographed and recorded respectively. 
Detection of Ku80 and COX-2 expression in 
xenograft tumor tissues 
Tumor tissues from the above treated animals were 
collected and placed in 10% formalin and were further 
embedded in paraffin for the following analysis. One part 
were used for protein extraction and further analyzed by 
western blot. The rest were embedded for histological 
analysis. A negative control was obtained by replacing the 
primary antibody of Ku80 or COX-2 with a normal rabbit 
or mouse IgG. The positive immunoreactive cells from 
each of the differently treated tumor tissue sections were 
measured at 200x magnification using a light microscope. 
The amount of proteins was analyzed by integral optical 
density (IOD) using IPP software (Image Plus Pro 6.0, 
Bethesda, MD, USA).
Co-Immunoprecipitation
To determine the interaction of CBP with Ku80, 
immunoprecipitation was performed as previously 
described. Nuclear extract proteins (300μg) prepared from 
H1299 cells were incubated respectively with a specific 
rabbit polyclonal antibody to Ku80 or a nonimmune rabbit 
IgG at a final concentration of 1 g/ mL each overnight at 
4°C. The immune complexes were pulled down by protein 
A/G agarose beads (Santa Cruz Biotechnology) and 
washed with PBS buffer containing proteinase inhibitor 
3 times. The immunoprecipitated proteins were separated 
by SDS-PAGE and analyzed by Western blotting using a 
CBP antibody.
Determination of acetylated Ku80
The nuclear extracts were immunoprecipitated with 
a specific antibody of pan-Acety or a nonimmune IgG as 
control and the immunoprecipitates were pulled down 
with protein A/G agarose beads. After extensive washing, 
the precipitated proteins were separated by SDS-PAGE gel 
and analyzed by Western blotting using a Ku80 antibody. 
Statistical analysis
Student’s t-tests were used to compare two 
independent groups of data. Survival curves were 
constructed using the Kaplane Meier method and were 
compared using the log-rank test. Statistical analyses were 
performed using the SPSS 16.0 software. The results were 
reported as the mean SE±SD. Values of P < 0.05 were 
considered to be statistically significant. 
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